Metallo-β-Lactamase Inhibitors for Antibacterial Resistance
A New Class of Metallo-β-lactamases Inhibitors Against Antibacterial Resistance
Tags: The University of Hong Kong, Hong Kong, Healthcare & Lifesciences
This invention introduces a new class of metallo-β-lactamase (MBL) inhibitors using FDA-approved bismuth compounds to combat bacterial resistance to β-lactam antibiotics. These compounds restore the efficacy of antibiotics such as amoxicillin and meropenem against MBL-producing resistant strains. Applications include pharmaceutical treatments for infections caused by antibiotic-resistant bacteria. In vitro and in vivo studies demonstrate the safety and effectiveness of these inhibitors in enhancing antibiotic action. Protected by US and PCT patents, this innovation addresses a critical global health threat posed by antibiotic resistance.
IP Type or Form Factor: Patent Pending; Process & Method; Platform
TRL: 4 - minimum viable product built in lab
Industry or Tech Area: Pharmaceutical Engineering; Biotechnology
